No accord for the ACCORD-Lipid trial results

Alsheikh-Ali, A. , Lin, J. , Abourjaily, P. , Ahearn, D. , Kuvin, J. and Karas, R. ( 2007) Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 100: 1499-1501.

Cannon, C. , Braunwald, E. , McCabe, C. , Rader, D. , Roulieau, J. , Belder, R. et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504.

Davidson, M. , Stein, E. , Bays, H. , Maki, K. , Doyle, R. , Schalwitz, R. et al. (2007) Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 19: 1354-1367.

FIELD Study Investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-1861.

Ginsberg, H. , Elam, M. , Lovato, L. , Crouse III, J. , Leiter, L. , Linz, P. et al.; ACCORD Study Group (2010 ) Effects of combination lipid therapy in type 2 diabetes mellitus . N Engl J Med 362: 1563-1574.

Greenstein, A. , Tavakoli, M. , Mojaddidi, M. , Al-Sunni, A. , Matfin, G. and Malik, R.A. ( 2007) Microvascular complications: evaluation and monitoring relevance to clinical practice, clinical trials, and drug development. Brit J Diabetes Vascular Dis 7: 166-171.

Grundy, S.M. , Cleeman, J.I. , Daniels, S.R. , Donato, K.S. , Eckel, R.H. , Frankliet, B.A. et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752.

Keech, A. , Mitchell, P. , Summanen, P. , O’Day, J.U. , Davis, T. , Moffitt, M. et al. (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (the FIELD study): a randomised controlled trial. Lancet 370: 1687-1697.

LaRosa, J. , Grundy, S. , Waters, D. , Shear, C. , Barter, P. , Fruchart, J. et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425-1435.

Leiter, L. , Feely, J. , Ferrieres, J.A. , Gitt, A. , Gonzalez-Juanatey, J. , Korsgaared Thomsen, K. et al. (2009) Characteristics of statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidemia International Study. World Diabetes Congress, Montreal: Canada, (Abstract D-0812).

National Institute for Health and Clinical Excellence ( 2010) Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (CG 67), http://www.nice.org.uk/CG067 (accessed 25 May 2010).

Robins, S.J. , Collins, D. , Wittes, J.T. , Papademetriou, V. , Deedwania, P.C. , Schaefer, E.J. et al. (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. J Am Med Assoc 285: 1585-1591.

Ryden, L. , Standl, E. , Bartnik, M. , Van den Berghe, G. , Betteridge, J. , de Boer, M.K. et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 28: 88-136.